Application of cerebrospinal fluid GZMA protein in preparation of neurosyphilis or nerve injury diagnosis product

By detecting the expression level of GZMA protein in cerebrospinal fluid, using GZMA protein or its specific antibodies, the problem of low CSF-RPR diagnosis sensitivity in the prior art is solved, and high sensitivity to early diagnosis of neurosyphilis and asymptomatic neurosyphilis is achieved Differentiation improves the accuracy of nerve damage assessment.

CN119064579APending Publication Date: 2024-12-03BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411256356.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing CSF-RPR diagnostic methods are less sensitive and it is difficult to diagnose asymptomatic neurosyphilis early, especially insensitive to the diagnosis of early neurosyphilis, and lack biological markers that effectively distinguish asymptomatic neurosyphilis from recessive syphilis.

Method used

Using GZMA protein or its specific antibodies as target molecules, the GZMA protein expression level in cerebrospinal fluid is detected through an enzyme-linked immunoassay kit or an immunohistochemistry kit, providing for early diagnosis, screening, typing and neurologic diagnosis, screening, typing and neurologic The product for injury assessment is judged in combination with the GZMA concentration value of cerebrospinal fluid.

Benefits of technology

It improves the sensitivity of early diagnosis of neurosyphilis, can effectively distinguish asymptomatic neurosyphilis from recessive syphilis, and achieves quantitative assessment of the degree of nerve damage, which is more sensitive and reliable than the existing technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064579A_ABST
    Figure CN119064579A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, in particular to Granzyme A (GZMA) as a cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. According to the invention, the concentration of GZMA protein in cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis, typing detection of asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, evaluation of nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. Compared with the prior art, the GZMA not only has higher sensitivity, but also can realize auxiliary diagnosis of the asymptomatic neurosyphilis, and is more beneficial to diagnosis and intervention of the asymptomatic neurosyphilis as early as possible.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to the use of cerebrospinal fluid GZMA protein and its specific antibody in the preparation of products for neurosyphilis screening, typing detection or assessment of the degree of nerve damage. Background Art

[0002] Neurosyphilis is a group of clinical syndromes in which Treponema pallidum invades the nervous system and causes damage to the meninges, brain, blood vessels or spinal cord. It can occur at all stages of the course of syphilis, not just in tertiary syphilis. The clinical manifestations of neurosyphilis vary, ranging from no clinical symptoms to complex clinical manifestations with extensive involvement of the nervous system. Clinically, it is usually divided into five types: asymptomatic, meningeal syphilis, meningeal vascular syphilis, tabes dorsalis and paralytic dementia (brain parenchymal syphilis). Although latent syphilis has no clinical symptoms, its harmfulness should be taken seriously. It can become recurrent syphilis and may progress to visceral and neurosyphilis. Patients with asymptomatic neurosyphilis have no obvious symptoms or signs, but there are abnormal changes in cerebrospinal fluid. If the abnormal cerebrospinal fluid persists for more than 5 years, the probability of developing symptomatic neurosyphilis is as high as 87%. In studies of primary and secondary syphilis, 20% of patients had abnormal cerebrospinal fluid, that is, neurosyphilis can occur in the early stages of syphilis. Early neurosyphilis includes syphilitic meningitis and vascular syphilis, and late neurosyphilis includes paralytic dementia, tabes dorsalis, etc. The incubation period of paralytic dementia is 10-15 years. Paralytic dementia is mainly manifested by mental and intellectual decline, such as memory loss, abnormal behavior, personality changes, and severe patients have epilepsy, stroke-like onset, secondary hemiplegia and aphasia.

[0003] Early diagnosis of neurosyphilis is very important. Finding sensitive biomarkers is helpful for the diagnosis of neurosyphilis and is of great significance for preventing serious and irreversible sequelae. At present, the diagnosis of neurosyphilis mainly relies on the examination of cerebrospinal fluid, including CSF-RPR, CSF white blood cell count and protein level. CSF-RPR is the same as the rapid plasma reagin ring card test in plasma. A positive result of this indicator can diagnose neurosyphilis. Important reference indicators for neurosyphilis also include cerebrospinal fluid cell count or protein level. When the CSF-RPR result is negative, if there are clinical signs of neurosyphilis, positive plasma tests and abnormal cerebrospinal fluid cell count, neurosyphilis can also be diagnosed. The increased protein content in the cerebrospinal fluid of patients with neurosyphilis is positively correlated with the severity of the disease and negatively correlated with the long-term prognosis. The increase in leukocytosis and the increase in protein content in the cerebrospinal fluid indicate the destruction of the blood-brain barrier and the presence of inflammatory reaction in the skull, which plays an auxiliary role in the diagnosis of neurosyphilis. However, the sensitivity of CSF-RPP was only 30%-70% during the diagnosis process, which is low and insensitive to the diagnosis of early asymptomatic neurosyphilis. At present, in the clinical diagnosis and treatment process, neurosyphilis is mainly diagnosed and treated in patients with symptoms of neurosyphilis. There is a lack of sensitive and reliable cerebrospinal biological markers that can effectively distinguish neurosyphilis, and there is an even greater lack of biological markers that can effectively distinguish asymptomatic neurosyphilis from latent syphilis.

[0004] GZMA is the most abundant protease present in cytotoxic granules and has been reported as a major toxicity mediator in vitro, but its role in the diagnosis of neurosyphilis has not been reported. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the technical problems that the existing CSF-RPR diagnostic method has low sensitivity and is insensitive to the diagnosis of early asymptomatic neurosyphilis, the present invention provides a cerebrospinal fluid / serum marker for early diagnosis screening, typing detection and nerve damage assessment of neurosyphilis. The marker can be used to achieve early diagnosis, screening, typing detection and nerve damage assessment of neurosyphilis. Compared with the existing technology, it has higher sensitivity and can effectively distinguish asymptomatic neurosyphilis from latent syphilis.

[0007] (II) Technical solution

[0008] In order to achieve the above object, the main technical solutions adopted by the present invention include:

[0009] In a first aspect, the present invention relates to GZMA as a cerebrospinal fluid marker for early diagnosis, screening and typing of patients with neurosyphilis.

[0010] In a second aspect, the present invention provides the use of GZMA protein or its specific antibody in the preparation of diagnostic products or auxiliary diagnostic products for neurosyphilis screening, typing detection or assessment of the degree of nerve damage; characterized in that the diagnostic product or auxiliary diagnostic product is a detection kit, antibody chip, antibody probe or detector with GZMA protein or its specific antibody as the target molecule.

[0011] According to a preferred embodiment of the present invention, the kit uses GZMA protein or its specific antibody as a target molecule to detect the expression level of GZMA protein or its specific antibody in cerebrospinal fluid.

[0012] According to a preferred embodiment of the present invention, the kit is an enzyme-linked immunosorbent assay kit or an immunohistochemistry kit.

[0013] According to a preferred embodiment of the present invention, the kit comprises: a primary antibody that can specifically recognize GZMA, a polypeptide dye, magnetic beads and a biotin-labeled secondary antibody. Preferably, the kit may include citrate buffer, PBS washing solution, peroxidase blocker, goat serum, streptomycin antibiotic-peroxidase, DAB solution and hematoxylin solution.

[0014] According to a preferred embodiment of the present invention, the kit further comprises reagents or materials for obtaining cerebrospinal fluid from the patient.

[0015] It should be noted that when detecting the expression level of GZMA protein, the Olink ultra-high sensitivity cerebrospinal fluid protein detection platform can also be used to quantify the expression level of GZMA.

[0016] In a third aspect, the present invention also relates to a product for early diagnosis, screening, typing detection or assessment of the degree of nerve damage in patients with neurosyphilis; the product can quantitatively detect the concentration of GZMA in the patient's ex vivo cerebrospinal fluid; the product is a detection kit, an antibody chip, an antibody probe or a detector; the product contains an antibody that specifically binds to GZMA.

[0017] Preferably, the product comprises antibodies that specifically bind to GZMA and other reagents that can quantitatively detect the concentration of GZMA protein in cerebrospinal fluid. The experimental method used in the examples of the present application is Olink Neurology Panel (95801), which can be used to detect 92 protein biomarkers related to neurological function, including GZMA protein.

[0018] In a fourth aspect, the present invention relates to an assessment system for the risk of nerve damage in patients with neurosyphilis, comprising a detection module and a judgment module, wherein the detection module is used to obtain the concentration value of GZMA in cerebrospinal fluid; the judgment module comprises a readable carrier storing a judgment rule;

[0019] The judgment rule is: when the cerebrospinal fluid GZMA concentration value obtained by the detection module is ≥3.782NPX value, it is judged as a moderate nerve injury risk; conversely, when 3.658NPX<GZMA concentration value<3.782NPX, it is judged as a low nerve injury risk;

[0020] When the cerebrospinal fluid GZMA concentration value obtained by the detection module is ≥3.658NPX, it is judged that there is a risk of cerebrospinal fluid infection with syphilis; otherwise, it is judged that there is no or low risk of cerebrospinal fluid infection with syphilis.

[0021] The reference value is the GZMA cut-off value obtained from the syphilis patient group; preferably, the cerebrospinal fluid cut-off value for diagnosing neurosyphilis (including asymptomatic neurosyphilis and symptomatic neurosyphilis) is 3.782NPX (a value greater than or equal to this value is judged as a moderate risk of nerve damage and can be diagnosed as neurosyphilis); the cerebrospinal fluid cut-off value for diagnosing asymptomatic neurosyphilis is 3.658NPX (a value lower than this value is judged as no or low risk of cerebrospinal fluid infection with syphilis and can be judged as non-neurosyphilis). The above cut-off value is the critical value of GZMA statistical analysis obtained from 88 syphilis patients.

[0022] In a fifth aspect, the present invention also provides a syphilis detection kit, which comprises: a first detection reagent composition for detecting the level of GZMA protein in cerebrospinal fluid; and a second detection reagent composition for detecting cerebrospinal fluid leukocytes and / or cerebrospinal fluid protein.

[0023] Alternatively, the present invention also provides a neurosyphilis diagnostic system, comprising: a first indicator analysis unit and a second analysis unit; the first analysis unit is an antibody chip or antibody probe for detecting the level of GZMA protein in cerebrospinal fluid; the second analysis unit is a detection reagent composition or analyzer for detecting the level of white blood cells or total protein in cerebrospinal fluid.

[0024] In the above scheme, when diagnosing neurosyphilis (including early diagnosis, typing and staging, and nerve damage assessment), the cerebrospinal fluid GZMA protein level can be combined with two or three indicators of cerebrospinal fluid leukocytes and cerebrospinal fluid proteins related to nerve damage in patients with neurosyphilis for early diagnosis, typing and staging, and nerve damage assessment of neurosyphilis.

[0025] Among them, the level of GZMA in cerebrospinal fluid is determined by Olink precision proteomics, which is a combination of antibody immunoassay and quantitative real-time PCR. The number of cerebrospinal fluid white blood cells and the amount of cerebrospinal fluid protein can be detected by known methods.

[0026] (III) Beneficial effects

[0027] The present invention provides a new cerebrospinal fluid marker GZMA for early diagnosis screening, typing detection and nerve damage assessment of neurosyphilis. By detecting the expression level of GZMA in the patient's cerebrospinal fluid, a quantitative assessment of the degree of nerve damage in patients with neurosyphilis can be achieved; or by detecting the expression level of GZMA in the patient's cerebrospinal fluid, neurosyphilis can be diagnosed, including early diagnosis and typing detection. The marker can be used to achieve early diagnosis, screening, typing detection and nerve damage assessment of neurosyphilis, with higher sensitivity than the existing technology. There is a significant difference in the expression level of GZMA in asymptomatic neurosyphilis and non-neurosyphilis; therefore, the cerebrospinal fluid marker GZMA is suitable for diagnosing and screening asymptomatic neurosyphilis. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The Olink method was used to detect the expression of GZMA protein in the cerebrospinal fluid and serum of three groups of syphilis patients with different types (latent, asymptomatic and symptomatic).

[0029] Figure 2 The results showed that the expression levels of GZMA in cerebrospinal fluid and serum were positively correlated with the neurological injury indicators cerebrospinal fluid protein and leukocytes.

[0030] Figure 3 To estimate the likelihood of a confirmed diagnosis of neurosyphilis (including asymptomatic neurosyphilis and symptomatic neurosyphilis) using cerebrospinal fluid and serum GZMA concentrations as the clinical outcome, and the area under the curve (AUC).

[0031] Figure 4 To distinguish asymptomatic neurosyphilis from non-neurosyphilis when asymptomatic neurosyphilis was the clinical outcome, the area under the curve (AUC) of different levels of cerebrospinal fluid and serum GZMA concentrations were used to assess the likelihood of a confirmed diagnosis of asymptomatic neurosyphilis.

[0032] Figure 5 All patients (including latent syphilis, asymptomatic neurosyphilis and symptomatic neurosyphilis) were divided into two groups according to the CSF GZMA cutoff value of 3.782NPX, and the differences in the neurological injury indicators CSF protein and leukocytes in each group were found.

[0033] Figure 6 Patients with latent syphilis and asymptomatic neurosyphilis were divided into two groups according to the cutoff value of cerebrospinal fluid GZMA 3.658NPX, and the differences in neurological damage indicators, cerebrospinal fluid protein and leukocytes, were found between the groups. DETAILED DESCRIPTION

[0034] In order to better explain the present invention, the present invention is now described in detail.

[0035] Early diagnosis of neurosyphilis is very important. Finding sensitive biomarkers is helpful for the diagnosis of neurosyphilis and is of great significance for preventing serious and irreversible sequelae. The inventors found through research that the levels of GZMA protein in the cerebrospinal fluid of patients with different types of syphilis are significantly different. The cerebrospinal fluid GZMA protein is significantly increased in patients with neurosyphilis, and is positively correlated with the nerve damage indicators cerebrospinal fluid protein and cerebrospinal fluid leukocytes, indicating that the cerebrospinal fluid GZMA protein can be used for the diagnosis of neurosyphilis and asymptomatic neurosyphilis, and can also indicate the severity of nerve damage. The cerebrospinal fluid GZMA protein level of patients with asymptomatic neurosyphilis is significantly higher than that of the non-neurosyphilis (latent syphilis) group, indicating that the GZMA protein level has changed in the early stage of neurosyphilis, that is, the asymptomatic neurosyphilis stage. Therefore, this biomarker can effectively distinguish asymptomatic neurosyphilis from latent syphilis.

[0036] During the study, the experiment first used the receiver operating characteristic curve (ROC) to show the diagnostic potential of GZMA protein in evaluating neurosyphilis (including asymptomatic neurosyphilis and symptomatic neurosyphilis); the experimental results showed that the area under the curve (AUC) of cerebrospinal fluid GZMA was 0.9032, P < 0.0001, which can be considered statistically significant, and its sensitivity was 93.33; the AUC of serum GZMA was 0.5516, P = 0.5307, which was considered not statistically significant. Based on this, the level of GZMA in the cerebrospinal fluid of patients with syphilis can better evaluate the occurrence of neurosyphilis.

[0037] Asymptomatic neurosyphilis is a difficult point in clinical diagnosis and treatment, because it is difficult to be discovered and diagnosed early without clinical symptoms. All syphilis patients need to undergo invasive cerebrospinal fluid screening, but in fact some patients are negative, but because there are no clinical symptoms, it is difficult to diagnose, so all syphilis patients need to be screened. In order to clarify the relationship between serum and cerebrospinal fluid GZMA and asymptomatic neurosyphilis, 45 patients with latent syphilis and asymptomatic neurosyphilis were studied in the following examples, and ROC was used to show the potential of GZMA to evaluate the occurrence of asymptomatic neurosyphilis; the experimental results showed that the AUC of cerebrospinal fluid GZMA was 0.8289, P = 0.0004, which was statistically significant; the AUC of serum GZMA was 0.6222, P = 0.1854. The above results show that the occurrence of asymptomatic neurosyphilis can be better evaluated according to the level of cerebrospinal fluid GZMA in syphilis patients, and whether serum can predict requires more samples for verification.

[0038] Further, the present invention divides all patients into two groups according to the GZMA ut-off value (3.782NPX) of cerebrospinal fluid of all syphilis patients (including latent syphilis, asymptomatic neurosyphilis and symptomatic neurosyphilis), and the cerebrospinal fluid protein and leukocytes of patients with cerebrospinal fluid damage above this value are significantly increased. Therefore, when the GZMA cerebrospinal fluid is lower than the 3.782NPX value, the risk of neurosyphilis in patients with neurosyphilis is low, and the risk of nerve damage is small; while the risk of neurosyphilis increases above this value, and the risk of nerve damage also increases. The present invention divides all patients into two groups according to the GZMA ut-off value (3.658NPX) of cerebrospinal fluid of syphilis patients (including latent syphilis and asymptomatic neurosyphilis), and the cerebrospinal fluid protein of patients with cerebrospinal fluid damage above this value is significantly increased, and the leukocytes also increase but not significantly. Therefore, when the GZMA value in cerebrospinal fluid is lower than 3.658NPX, the risk of asymptomatic neurosyphilis and nerve damage in patients with neurosyphilis is lower; while when the value is higher than this value, the risk of asymptomatic neurosyphilis and nerve damage increases.

[0039] In summary, the present invention provides the application of GZMA as an early diagnosis of neurosyphilis and an assessment of asymptomatic nerve damage. The inventors use the GZMA protein level in cerebrospinal fluid as a reliable and effective primary reference indicator or auxiliary reference indicator for early diagnosis, typing and nerve damage assessment of syphilis. Based on the above findings, the present invention can detect the expression level of GZMA in cerebrospinal fluid to achieve high-sensitivity detection and typing of syphilis, especially neurosyphilis, and can also accurately quantify and evaluate nerve damage, supervision and treatment of neurosyphilis.

[0040] In order to better understand the above technical solution, exemplary embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although exemplary embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided to enable a clearer and more thorough understanding of the present invention and to fully convey the scope of the present invention to those skilled in the art.

[0041] The experimental methods in the following experimental examples are conventional methods unless otherwise specified. The raw materials and reagents used in the following examples are commercially available products unless otherwise specified. Related technical contents include:

[0042] 1. Research subjects

[0043] With informed consent and meeting the inclusion criteria, 88 cases were selected for inclusion, including 15 cases of latent syphilis, 30 cases of asymptomatic neurosyphilis and 43 cases of paralytic dementia, to establish a neurosyphilis cohort of different severity. The diagnostic criteria were implemented according to the WS273-2007 syphilis diagnostic criteria.

[0044] (II) Sample collection

[0045] According to the conditions of the enrolled patients, lumbar puncture and cubital venipuncture were performed to obtain cerebrospinal fluid and blood for routine tests, and cerebrospinal fluid and serum samples were collected. With the informed consent of the patients, 5 mL of cerebrospinal fluid was collected by lumbar puncture, and 10 mL of blood samples were collected by vein. After the cerebrospinal fluid was collected by lumbar puncture, it was packaged in cryopreservation tubes and coded and labeled; after the blood was collected by venipuncture, it was placed in a 4°C centrifuge and centrifuged for 10 minutes at 2000 rpm to quickly separate the upper serum and place it in a cryopreservation tube.

[0046] (III) Detection of GZMA concentration in serum and cerebrospinal fluid using the Olink method

[0047] Olink neurology panel (95801) was used to detect 92 proteins related to neurological function, including GZMA protein. Olink precision proteomics is a precise proteomics research tool that is very suitable for large-scale screening, with good sensitivity, rapidity, high-throughput analysis, and specificity at the multiple channel level. Therefore, this example uses Olink to detect markers in the serum and cerebrospinal fluid of patients with different types of neurosyphilis, and it is found that GZMA protein has significant differences in cerebrospinal fluid. The detection of cerebrospinal fluid protein and cerebrospinal fluid leukocytes is carried out according to the method described in WS273-2007.

[0048] The following statistics and data analysis are performed on the above Olink test results:

[0049] (1) GZMA protein is significantly increased in cerebrospinal fluid and serum of neurosyphilis

[0050] Olink precision proteomics was used to detect the difference in the expression of nerve-related proteins in serum and cerebrospinal fluid, and GZMA protein was screened out with significant differences in cerebrospinal fluid, but no significant differences in serum. Figure 1 As shown in Table 1. It was found that the GZMA in the cerebrospinal fluid of patients with symptomatic neurosyphilis (symptomatic) and asymptomatic neurosyphilis (asymptomatic) was significantly increased compared with latent syphilis, and there was also a significant difference between patients with symptomatic neurosyphilis and asymptomatic neurosyphilis. However, there was no significant difference in serum GZMA among the three groups. Therefore, the cerebrospinal fluid GZMA level can be used to distinguish syphilis typing and indicate the severity of nerve damage.

[0051] Figure 1 In Figure (a), latent syphilis means non-neurosyphilis, asymptomatic means asymptomatic neurosyphilis, and symptomatic means paralytic dementia, i.e. symptomatic neurosyphilis. Figure 1As can be seen from Figure (a), the GZMA concentration in the cerebrospinal fluid of patients with symptomatic neurosyphilis is greater than the GZMA concentration in the cerebrospinal fluid of patients with asymptomatic neurosyphilis and greater than the GZMA concentration in the cerebrospinal fluid of patients with latent syphilis; Figure 1 As shown in Figure (b), there was no significant difference in GZMA concentration in the serum of patients with symptomatic neurosyphilis, asymptomatic neurosyphilis and latent syphilis.

[0052] Table 1: Statistical data of differences in GMZA expression in cerebrospinal fluid among three different syphilis types

[0053]

[0054] In Table 1: Latent syphilis & asymptomatic represents the statistical value of the difference in GMZA concentration between latent syphilis and asymptomatic neurosyphilis in cerebrospinal fluid or serum. Latent syphilis & symptomatic represents the statistical value of the difference in GMZA concentration between latent syphilis and symptomatic neurosyphilis in cerebrospinal fluid or serum. Asymptomatic & symptomatic represents the statistical value of the difference in GMZA concentration between asymptomatic neurosyphilis and symptomatic neurosyphilis in cerebrospinal fluid or serum. Mean difference The mean difference reflects the average difference between each marker value and the arithmetic mean. The difference value can show whether there is a significant difference between the two groups, and the difference multiple can show the multiple of this difference. It can be seen from the statistics in Table 1 that there are significant differences in the GZMA protein levels in the cerebrospinal fluid of patients with different types of syphilis, and the differences are statistically significant.

[0055] (2) GZMA in cerebrospinal fluid is significantly positively correlated with injury indicators in cerebrospinal fluid

[0056] Important reference indicators for neurosyphilis are cerebrospinal fluid cell count and protein level. Patients with neurosyphilis will have abnormal cerebrospinal fluid cell count and protein level, and these two indicators can also indicate the severity of neurosyphilis damage. This experiment used microscope counting and blood analyzer counting methods to count cerebrospinal fluid cells in three groups of syphilis patients with different types, and Lee-Vinson was used to measure the protein level in the cerebrospinal fluid.

[0057] Combination Figure 2 As shown in Figures (a) and (b), the expression level of GZMA protein in cerebrospinal fluid is significantly positively correlated with the protein in the patient's cerebrospinal fluid (correlation coefficient R = 0.4281, p < 0.0001) and the number of white blood cells (correlation coefficient R = 0.6089, p < 0.0001). Therefore, GZMA protein in cerebrospinal fluid can indicate abnormalities in protein and white blood cells in cerebrospinal fluid. However, combined with Figure 2 As shown in Figures (c) and (d), there is no significant correlation between the expression level of GZMA protein in serum and the protein in the cerebrospinal fluid of patients (correlation coefficient R=0.07827, p=0.4685) and the number of white blood cells (correlation coefficient R=0.04409, p=0.6833).

[0058] It can be seen that the GZMA protein level in the cerebrospinal fluid of syphilis patients is positively correlated with the patient's spinal fluid cell count and protein level. Therefore, in practice, the cerebrospinal fluid cell count and / or protein level can be used as a reference indicator, together with the GZMA protein level in the cerebrospinal fluid, as a means of early diagnosis and screening of neurosyphilis, typing detection, and quantitative assessment of the degree of nerve damage.

[0059] (3) Evaluation of cerebrospinal fluid GZMA in the detection of neurosyphilis in syphilis patients

[0060] The study used the receiver operating characteristic curve (ROC) to evaluate the diagnostic potential of GZMA in evaluating neurosyphilis (neurosyphilis includes asymptomatic neurosyphilis and symptomatic neurosyphilis). Figure 3 As shown in the figure, the experimental results are: the area under the curve of cerebrospinal fluid GZMA AUC (0.9032 [95% CI 0.8372-0.9692]), P < 0.0001, which can be considered statistically significant (see Figure (a)); the area under the curve of serum GZMA AUC (0.5516), P = 0.5307, which is considered not statistically significant (see Figure (b)). This shows that the level of cerebrospinal fluid GZMA in syphilis patients can better assist the diagnosis of neurosyphilis, with a sensitivity of 93.33, which is highly sensitive.

[0061] In addition to the above detection effects, the level of cerebrospinal fluid GZMA can also be used to diagnose asymptomatic neurosyphilis in neurosyphilis. In order to further clarify the relationship between serum and cerebrospinal fluid GZMA and asymptomatic neurosyphilis, this example studied 45 patients with latent syphilis and asymptomatic neurosyphilis. The study used ROC to evaluate the potential of GZMA in syphilis patients (including latent syphilis patients and asymptomatic neurosyphilis patients) to evaluate the diagnosis of symptomatic neurosyphilis. Figure 4 The experimental results are as follows: the area under the curve of GZMA in cerebrospinal fluid (AUC) was 0.8289 [95% CI 0.7124-0.9454], P = 0.0004 was considered statistically significant (see Figure 4 (a) Figure); The area under the curve of serum GZMA AUC (0.6222), P = 0.1854, no significant significance (see Figure 4 (b) Figure). The above results show that the occurrence of asymptomatic neurosyphilis can be better evaluated according to the level of GZMA in the cerebrospinal fluid of patients with neurosyphilis, with a sensitivity of 86.67, which has a high sensitivity.

[0062] (4) GZMA levels can indicate damage indicators in cerebrospinal fluid

[0063] All syphilis patients were divided into two groups according to the cut-off value of the cerebrospinal fluid GZMA level (3.782NPX value). Figure 5 As shown, the concentration of GZMA in the cerebrospinal fluid of patients with cerebrospinal fluid injury was higher than 3.782NPX value. Figure 5 (a)) increased significantly, and the white blood cell increased less significantly (see Figure 5 (b) Figure). Therefore, patients with CSF GZMA concentrations below 3.782NPX have a low risk of neurosyphilis and a small risk of nerve damage, while patients with CSF GZMA concentrations above this value have a relatively high risk of neurosyphilis and an increased risk of nerve damage.

[0064] It was further found that according to the cut-off value of the cerebrospinal fluid GZMA level (3.658NPX value), patients with latent syphilis and asymptomatic neurosyphilis were divided into two groups. Figure 6 As shown in the figure, when the CSF GZMA concentration is higher than 3.658NPX, the patient's CSF leukocytes, an indicator of CSF damage, increased significantly (see Figure (b)), and the protein also tended to increase. Therefore, when the CSF GZMA concentration is higher than 3.658NPX, the risk of asymptomatic neurosyphilis and nerve damage in syphilis patients increases; when the CSF GZMA concentration is lower than 3.658NPX, the risk of neurosyphilis and nerve damage in syphilis patients decreases. When the CSF GZMA concentration is ≥3.782NPX, the risk of neurosyphilis in syphilis patients increases further.

[0065] In summary, the concentration of GZMA protein in cerebrospinal fluid can be used as an indicator for early diagnosis of neurosyphilis, typing of neurosyphilis (including asymptomatic neurosyphilis) and latent syphilis, and evaluation of the degree of nerve damage. It can be used alone or as a main reference indicator in combination with other indicators to complete the diagnostic screening, typing and nerve damage evaluation of syphilis.

[0066] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention is described in detail with reference to the embodiments, it should be understood by those skilled in the art that any modification or equivalent replacement of the technical solutions of the present invention does not depart from the spirit and scope of the technical solutions of the present invention and should be included in the scope of the claims of the present invention.

Claims

1. GZMA is used as a cerebrospinal fluid marker for early diagnosis, screening and typing of patients with neurosyphilis.

2. Use of GZMA protein or its specific antibody in the preparation of diagnostic products or auxiliary diagnostic products for neurosyphilis screening, typing detection or assessment of the degree of nerve damage; characterized in that, The diagnostic product or auxiliary diagnostic product is a detection kit, antibody chip, antibody probe or detector using GZMA protein or its specific antibody as the target molecule.

3. The use according to claim 2, characterized in that: The kit uses GZMA protein or its specific antibody as a target molecule to detect the expression level of GZMA protein or its specific antibody in cerebrospinal fluid.

4. The use according to claim 2, characterized in that: The kit is an enzyme-linked immunosorbent assay kit or an immunohistochemistry kit.

5. The use according to claim 2, characterized in that: The kit comprises: a primary antibody capable of specifically recognizing GZMA, a polypeptide dye, magnetic beads and a secondary antibody labeled with biotin.

6. The use according to claim 5, characterized in that: The kit also includes reagents or materials for obtaining cerebrospinal fluid from the patient.

7. Products for early diagnosis, screening, typing or assessment of nerve damage in patients with neurosyphilis; characterized in that: The product can quantitatively detect the concentration of GZMA in the patient's ex vivo cerebrospinal fluid; the product is a detection kit, an antibody chip, an antibody probe or a detector; the product contains an antibody that specifically binds to GZMA.

8. A syphilis detection kit, characterized in that: include: A first detection reagent composition for detecting the level of GZMA protein in cerebrospinal fluid; and a second detection reagent composition for detecting cerebrospinal fluid leukocytes and / or cerebrospinal fluid proteins.

9. A neurosyphilis diagnostic system, characterized in that: include: A first indicator analysis unit and a second analysis unit; the first analysis unit is an antibody chip or an antibody probe for detecting the level of GZMA protein in cerebrospinal fluid; The second analysis unit is a detection reagent composition or an analyzer for detecting the level of leukocytes or total protein in cerebrospinal fluid.

10. A system for assessing the risk of nerve damage in patients with neurosyphilis, characterized in that: It includes a detection module and a judgment module; wherein the detection module is used to obtain the concentration value of GZMA in cerebrospinal fluid; the judgment module includes a readable carrier storing judgment rules; The judgment rule is: when the cerebrospinal fluid GZMA concentration value obtained by the detection module is ≥3.782NPX value, it is judged as a moderate nerve injury risk; conversely, when 3.658NPX<GZMA concentration value<3.782NPX, it is judged as a low nerve injury risk; When the cerebrospinal fluid GZMA concentration value obtained by the detection module is ≥3.658NPX, it is judged that there is a risk of cerebrospinal fluid infection with syphilis; otherwise, it is judged that there is no or low risk of cerebrospinal fluid infection with syphilis.

Citation Information

Cited By

  • Application of cerebrospinal fluid CTSC protein as marker in preparation of neurosyphilis or nerve injury diagnosis product

    CN119414032A